Esperion Therapeutics (ESPR) Cost of Revenue (2020 - 2026)

Esperion Therapeutics has reported Cost of Revenue for 7 years, with the latest figure at $34.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 9.62% year-over-year to $34.6 million; the trailing twelve-month figure through Mar 2026 stood at $135.9 million (up 50.94% YoY), and the FY2024 full-year result was $68.6 million, up 58.55% from the prior year.
• Cost of Revenue for Q1 2026 stood at $34.6 million, down from $41.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $41.3 million in Q3 2025, with the low at $4.2 million in Q4 2022.
• Historically, Cost of Revenue has averaged $17.2 million across 5 years, with a median of $12.5 million in 2023.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 409.78% — and 2023, when it decreased 26.05%.
• Esperion Therapeutics' Cost of Revenue stood at $4.2 million in 2022, then surged by 175.29% to $11.5 million in 2023, then jumped by 123.81% to $25.6 million in 2024, then soared by 61.09% to $41.3 million in 2025, then fell by 16.27% to $34.6 million in 2026.
• The last three Cost of Revenue figures came in at $34.6 million (Q1 2026), $41.3 million (Q3 2025), and $28.5 million (Q2 2025), per Business Quant data.